银屑病患者全身治疗应答的生物标志物:范围综述
该范围综述系统检索了CENTRAL、Embase、LILACS和MEDLINE(1990年至2021年12月),纳入71项研究(67项研究疗效结局,8项研究安全性结局,4项两者均研究),鉴定并编录银屑病全身治疗应答的候选生物标志物。多数研究(48项)报告与生物制剂应答相关的基因组或蛋白质组生物标志物,但方法学局限常见。候选生物标志物需进一步验证才能用于临床。
要点
- 多数研究(48项)报告与生物制剂应答相关的基因组或蛋白质组生物标志物。
- 肿瘤坏死因子抑制剂疗效候选标志物包括CARD14、CDKAL1、IL1B、IL12B和IL17RA位点变异及2型树突状细胞中脂多糖诱导的NF-κB磷酸化。
- 乌司奴单抗疗效候选标志物包括HLA-C*06:02和IL1B位点变异,均需进一步验证。
核心结论
- 该综述提供了银屑病全身治疗应答生物标志物的综合目录,但所鉴定候选生物标志物需在方法学稳健的研究中进一步评估以确定潜在临床效用。
研究设计与样本
- 范围综述,系统检索CENTRAL、Embase、LILACS和MEDLINE中1990年至2021年12月发表的相关文章。
- 纳入标准为涉及银屑病患者(任何年龄,n ≥ 50)且报告与全身治疗应答相关生物标志物的研究。
- 共纳入71项研究,其中67项研究疗效结局,8项研究安全性结局,4项同时研究两者。
- 数据由一名评审员提取并由第二名评审员核对;符合最低质量标准的 study 正式评估偏倚。
主要发现
- 多数研究报告与生物制剂应答相关的基因组或蛋白质组生物标志物(48项研究)。
- 方法学或报告局限性频繁影响结果解读,包括对关键协变量控制不足、缺乏多重检验调整和选择性结局报告。
- 肿瘤坏死因子抑制剂疗效候选生物标志物包括CARD14、CDKAL1、IL1B、IL12B和IL17RA位点变异,以及2型树突状细胞中脂多糖诱导的核因子(NF)-κB磷酸化。
- 乌司奴单抗疗效候选生物标志物包括HLA-C*06:02和IL1B位点变异。
- 候选生物标志物参与银屑病发病机制中的免疫细胞串扰,最显著涉及抗原呈递、Th17细胞分化、NF-κB正调控和Th17细胞活化。
关键数值与推荐
- 纳入研究需涉及银屑病患者(任何年龄,n ≥ 50)并报告与全身治疗应答相关的生物标志物。
- 候选生物标志物由专家多利益相关方组通过多数投票共识程序鉴定,并映射至相关细胞和分子通路。
- 无生物标志物有足够证据支持临床使用而不经进一步验证研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 方法学或报告局限性频繁影响结果解读,包括对关键协变量控制不足、缺乏多重检验调整和选择性结局报告。
- 所鉴定候选生物标志物需在方法学稳健的研究中进一步评估以确定潜在临床效用。
- 未来研究应旨在解决本综述强调的常见方法学局限性,以加速临床用生物标志物的发现和验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Responses to the systemic treatments commonly used to treat psoriasis vary. Biomarkers that accurately predict effectiveness and safety would enable targeted treatment selection, improved patient outcomes and more cost-effective healthcare. OBJECTIVES: To perform a scoping review to identify and catalogue candidate biomarkers of systemic treatment response in psoriasis for the translational research community. METHODS: A systematic search of CENTRAL, Embase, LILACS and MEDLINE was performed for relevant articles published between 1990 and December 2021. Eligibility criteria were studies involving patients with psoriasis (any age, n ≥ 50) reporting biomarkers associated with systemic treatment response. The main outcomes were any measure of systemic treatment efficacy or safety. Data were extracted by one reviewer and checked by a second; studies meeting minimal quality criteria (use of methods to control for confounding) were formally assessed for bias. Candidate biomarkers were identified by an expert multistakeholder group using a majority voting consensus exercise and mapped to relevant cellular and molecular pathways. RESULTS: Of 71 included studies (67 studying effectiveness outcomes and eight safety outcomes; four studied both), most reported genomic or proteomic biomarkers associated with response to biologics (48 studies). Methodological or reporting limitations frequently compromised the interpretation of findings, including inadequate control for key covariates, lack of adjustment for multiple testing, and selective outcome reporting. We identified candidate biomarkers of efficacy to tumour necrosis factor inhibitors [variation in CARD14, CDKAL1, IL1B, IL12B and IL17RA loci, and lipopolysaccharide-induced phosphorylation of nuclear factor (NF)-κB in type 2 dendritic cells] and ustekinumab (HLA-C*06:02 and variation in an IL1B locus). None were supported by sufficient evidence for clinical use without further validation studies. Candidate biomarkers were found to be involved in the immune cellular crosstalk implicated in psoriasis pathogenesis, most notably antigen presentation, T helper (Th)17 cell differentiation, positive regulation of NF-κB, and Th17 cell activation. CONCLUSIONS: This comprehensive catalogue provides a key resource for researchers and reveals a diverse range of biomarker types and outcomes in the included studies. The candidate biomarkers identified require further evaluation in methodologically robust studies to establish potential clinical utility. Future studies should aim to address the common methodological limitations highlighted in this review to expedite discovery and validation of biomarkers for clinical use. What is already known about this topic? Responses to the systemic treatments commonly used to treat psoriasis vary. Biomarkers that accurately predict effectiveness and safety would enable targeted treatment selection, improved patient outcomes and more cost-effective healthcare. What does this study add? This review provides a comprehensive catalogue of investigated biomarkers of systemic treatment response in psoriasis. A diverse range of biomarker types and outcomes was found in the included studies, serving as a key resource for the translational research community.
引用
- Corbett M, Ramessur R, Marshall D, et al. Biomarkers of systemic treatment response in people with psoriasis: a scoping review. Br J Dermatol. 2022. PMID: 35606928. doi:10.1111/bjd.21677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。